Alkermes Plc (NASDAQ:ALKS) Director Richard F. Pops sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $57.42, for a total value of $1,435,500.00. Following the completion of the sale, the director now directly owns 649,137 shares in the company, valued at $37,273,446.54. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of Alkermes Plc (NASDAQ:ALKS) traded down 0.53% during midday trading on Thursday, hitting $57.94. The company had a trading volume of 937,507 shares. Alkermes Plc has a one year low of $39.36 and a one year high of $62.50. The firm’s market cap is $8.88 billion. The company’s 50 day moving average is $57.81 and its 200 day moving average is $57.06.

Alkermes Plc (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, April 27th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.07. Alkermes Plc had a negative return on equity of 12.75% and a negative net margin of 36.92%. The business had revenue of $191.80 million for the quarter, compared to analyst estimates of $195.79 million. During the same period in the prior year, the firm posted ($0.16) EPS. Alkermes Plc’s revenue for the quarter was up 22.3% on a year-over-year basis. Equities analysts forecast that Alkermes Plc will post ($0.04) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Alkermes Plc (NASDAQ:ALKS)

TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/05/25/alkermes-plc-alks-director-richard-f-pops-sells-25000-shares-2.html.

Several institutional investors have recently bought and sold shares of ALKS. Greenwood Capital Associates LLC purchased a new position in Alkermes Plc during the fourth quarter valued at approximately $202,000. Mn Services Vermogensbeheer B.V. raised its stake in Alkermes Plc by 5.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 4,053 shares of the company’s stock valued at $222,000 after buying an additional 224 shares in the last quarter. Achmea Investment Management B.V. bought a new stake in Alkermes Plc during the first quarter valued at $247,000. Nomura Holdings Inc. bought a new stake in Alkermes Plc during the first quarter valued at $266,000. Finally, Decatur Capital Management Inc. bought a new stake in Alkermes Plc during the first quarter valued at $267,000. 95.52% of the stock is owned by institutional investors and hedge funds.

ALKS has been the topic of a number of research reports. Cantor Fitzgerald restated a “neutral” rating and issued a $51.00 price objective on shares of Alkermes Plc in a report on Thursday, February 16th. TheStreet upgraded Alkermes Plc from a “d+” rating to a “c” rating in a report on Wednesday, February 15th. Cowen and Company restated a “positive” rating and issued a $65.00 price objective on shares of Alkermes Plc in a report on Tuesday, March 21st. Jefferies Group LLC restated a “buy” rating and issued a $70.00 price objective on shares of Alkermes Plc in a report on Monday, April 3rd. Finally, Morgan Stanley restated an “equal weight” rating and issued a $62.00 price objective on shares of Alkermes Plc in a report on Monday, April 24th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $63.55.

About Alkermes Plc

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

12 Month Chart for NASDAQ:ALKS

Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with MarketBeat.com's FREE daily email newsletter.